Research programme: methionine aminopeptidase inhibitors - Larimar Therapeutics
Alternative Names: ZGN 1258; ZGN 1345; ZGN 839; ZGN-201Latest Information Update: 28 Jun 2022
At a glance
- Originator Zafgen
- Developer Larimar Therapeutics
- Class Anti-inflammatories; Hepatoprotectants; Obesity therapies; Small molecules
- Mechanism of Action Methionine aminopeptidase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Non-alcoholic steatohepatitis; Obesity; Prader-Willi syndrome
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)
- 28 Feb 2022 No recent reports of development identified for preclinical development in Prader-Willi-syndrome in USA
- 28 Apr 2021 No recent reports of development identified for preclinical development in Inflammation in USA (PO)